


Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-A2B4BAD1-1DF8-4F72-9C3F-C9CA83E50529_3_en-US
DOI: https://doi.org/10.31003/USPNF_M7136_03_01
DOI Ref: ydl7l

© 2025 USPC
Do not distribute

Abiraterone Acetate



$C_{26}H_{33}NO_2$ 391.55
Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3 β);
17-(Pyridin-3-yl)androsta-5,16-dien-3-yl acetate CAS RN[®]: 154229-18-2; UNII: EM5OCB9YJ6.

DEFINITION
Abiraterone Acetate contains NLT 98.0% and NMT 102.0% of abiraterone acetate ($C_{26}H_{33}NO_2$), calculated on the as-is basis.

IDENTIFICATION

Change to read:

- **A.** [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K ▲](#) (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• **PROCEDURE**

Solution A: 10 mM of ammonium acetate in water

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Acetonitrile (%)	Ethanol (%)
0	50	20	30
40	15	55	30
47	0	20	80
58	0	20	80
60	50	20	30
70	50	20	30

[NOTE—Protect solutions from light.]

System suitability solution: 0.625 mg/mL of [USP Abiraterone System Suitability Mixture RS](#) in acetonitrile. [NOTE—See [Table 2](#) for relative retention times of the main components of the mixture.]

Table 2

Name	Relative Retention Time
7-Ketoabiraterone acetate	0.42

Name	Relative Retention Time
α-Epoxyabiraterone acetate	0.62
β-Epoxyabiraterone acetate	0.66
Abiraterone	0.69
3-Deoxy-3-acetyl abiraterone-3-ene	0.85
Abiraterone acetate	1.0
Abiraterone ethyl ether	1.18
Abiraterone isopropyl ether	1.26
Anhydro abiraterone	1.29
3-Deoxy 3-chloroabiraterone	1.31
O-Chlorobutylabiraterone	1.33

Standard solution: 0.625 mg/mL of [USP Abiraterone Acetate RS](#) in acetonitrile

Sample solution: 0.625 mg/mL of Abiraterone Acetate in acetonitrile

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 3-mm × 15-cm; 3-μm packing L1

Column temperature: 15°

Flow rate: 0.45 mL/min

Injection volume: 10 μL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.0 between anhydro abiraterone and 3-deoxy 3-chloroabiraterone peaks, *System suitability solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of abiraterone acetate ($C_{26}H_{33}NO_2$) in the portion of Abiraterone Acetate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Abiraterone Acetate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Abiraterone Acetate in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the as-is basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

[NOTE—Protect solutions from light.]

Solution A, Mobile phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Sensitivity solution: 0.3 μg/mL of [USP Abiraterone Acetate RS](#) in acetonitrile, from *Standard solution*

System suitability

Samples: *System suitability solution*, *Standard solution*, and *Sensitivity solution*

Suitability requirements**Resolution:** NLT 1.0 between anhydro abiraterone and 3-deoxy 3-chloroabiraterone peaks, *System suitability solution***Signal-to-noise ratio:** NLT 10, *Sensitivity solution***Relative standard deviation:** NMT 0.73%, *Standard solution***Analysis****Samples:** *Standard solution and Sample solution*

Calculate the percentage of each impurity in the portion of Abiraterone Acetate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

 r_U = peak area of each impurity from the *Sample solution* r_S = peak area of abiraterone acetate from the *Standard solution* C_S = concentration of [USP Abiraterone Acetate RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Abiraterone Acetate in the *Sample solution* (mg/mL) F = relative response factor for each individual impurity (see [Table 3](#))**Acceptance criteria:** See [Table 3](#). Disregard any peak less than 0.05%.**Table 3**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
α -Epoxyabiraterone acetate	0.62	0.26	0.25
β -Epoxyabiraterone acetate	0.66	0.26	0.25
Abiraterone	0.69	1.0	0.20
Abiraterone acetate	1.0	—	—
Abiraterone ethyl ether	1.18	1.0	0.20
Abiraterone isopropyl ether	1.26	1.0	0.20
Unspecified impurity	—	1.0	0.10
Total impurities	—	—	0.80

SPECIFIC TESTS

- [WATER DETERMINATION, Method Ic\(921\)](#): NMT 0.25%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature and protect from light.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Abiraterone Acetate RS](#)[USP Abiraterone System Suitability Mixture RS](#)

It contains Abiraterone Acetate and small amounts of the following:

Abiraterone

17-(Pyridin-3-yl)androsta-5,16-dien-3 β -ol.C₂₄H₃₁NO 349.52

Abiraterone ethyl ether

3 β -Ethoxy-17-(pyridin-3-yl)androsta-5,16-diene.C₂₆H₃₅NO 377.57

Abiraterone isopropyl ether

3 β -Isopropoxy-17-(pyridin-3-yl)androsta-5,16-diene.C₂₇H₃₇NO 391.60

Anhydro abiraterone
17-(Pyridin-3-yl)androsta-3,5,16-triene.
 $C_{24}H_{29}N$ 331.50
O-Chlorobutylabiraterone
3β-(4-Chlorobutoxy)-17-(pyridin-3-yl)androsta-5,16-diene.
 $C_{28}H_{38}ClNO$ 440.07
3-Deoxy-3-acetyl abiraterone-3-ene
1-[17-(Pyridin-3-yl)androsta-3,5,16-trien-3-yl]ethanone.
 $C_{26}H_{31}NO$ 373.53
3-Deoxy 3-chloroabiraterone
3β-Chloro-17-(pyridin-3-yl)androsta-5,16-diene.
 $C_{24}H_{30}ClN$ 367.96
α-Epoxyabiraterone acetate
17-(Pyridin-3-yl)-16α,17α-epoxyandrost-5-en-3β-yl acetate.
 $C_{26}H_{33}NO_3$ 407.55
β-Epoxyabiraterone acetate
17-(Pyridin-3-yl)-16β,17β-epoxyandrost-5-en-3β-yl acetate.
 $C_{26}H_{33}NO_3$ 407.55
7-Ketoabiraterone acetate
7-Oxo-17-(pyridin-3-yl)androsta-5,16-dien-3β-yl acetate.
 $C_{26}H_{31}NO_3$ 405.54

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ABIRATERONE ACETATE	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(6)

Current DocID: GUID-A2B4BAD1-1DF8-4F72-9C3F-C9CA83E50529_3_en-US

DOI: https://doi.org/10.31003/USPNF_M7136_03_01

DOI ref: [ydl7l](#)